Michigan-based Esperion on Oct. 18 announced a plan to reduce the company’s overall workforce by 40 percent and significantly decrease operational expenses in fiscal years 2021 and 2022 to optimize long-term growth.

Veta Health, a leading global provider of digital solutions for remote patient care and chronic condition monitoring, announced that James Sutcliffe was named chief executive officer.

The Greater Than One (GTO) Group announced the introduction of a new operating model to better serve clients outside the United States. Referred to as OUS (Outside United States) On-Demand, the new model will bring the same level of service innovation and value creation abroad as US-based clients experience today.

The COVID-19 pandemic altered the trajectory of healthcare, but what about healthcare marketing? As part of its Next series, IPG Health brought together experts from across the network and the industry to talk about the emerging trends and technologies that are accelerating innovation in health. FCB Health Chief Product Officer Graham Johnson discusses a few key trends that marketers should pay attention to in looking toward the future.

GlaxoSmithKline announced the British pharma leader’s intention to leave the sprawling campus in Research Triangle Park, N.C. for the more compact confines of a downtown Durham, N.C. space.

After serving three presidential administrations, Dr. Francis S. Collins is stepping down as director of the National Institutes of Health at the end of 2021 with a successor yet to be named.

Mike Hidock, Director of Quality and Compliance Services at IQVIA, analyzes key considerations for preparing quality management systems (QMS) for fast tracked COVID-19 treatment approvals.

Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for the company’s one-shot Covid-19 vaccine this week. In other news, President Biden’s chief medical advisor Dr. Anthony Fauci told CNBC that they expect the FDA to review data on Merck and Ridgeback Biotherapeutics’ new oral antiviral against Covid-19 “as quickly as they possibly can.”

A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of Covid-19, researchers suggested in a report. In other news, Gilead Sciences Inc.’s intravenous antiviral drug remdesivir helped keep high-risk Covid-19 patients out of the hospital in a randomized trial.

A study out of Oxford University’s Leverhulme Centre for Demographic Science found that the Covid-19 pandemic has resulted in the largest drop in life expectancy in western Europe since World War II.